• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population 5
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative 1
• mNSCLC - L1 - PDL1 positive 14
• mNSCLC - L1 - TMB>10Mb 1
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population 3
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT) 6
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population 4
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab plus SoC
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus carboplatin plus paclitaxel
• atezolizumab plus pemetrexed and platin
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab and pemetrexed plus platin
• pembrolizumab plus SoC
• sintilimab based treatment
• sintillimab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• pembrolizumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel
• vs nab-paclitaxel
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs atezolizumab based treatment
• vs atezolizumab plus carboplatin plus nab-paclitaxel
• vs pembrolizumab based treatment
• vs pembrolizumab alone
• vs pembrolizumab plus placebo
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus carboplatin and paclitaxel

  All patients Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), nivolumab plus ipilimumab plus SoC vs. platinum association, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;